
|Videos|August 3, 2017
Dr. Feldman on Challenges Facing the Development of Biomarkers for Prostate Cancer
Author(s)Adam Scott Feldman, MD, MPH
Adam Scott Feldman, MD, MPH, urologist at Massachusetts General Hospital, assistant professor of surgery, Harvard Medical School, discusses challenges facing the development of biomarkers for patients with prostate cancer.
Advertisement
Adam Scott Feldman, MD, MPH, urologist at Massachusetts General Hospital, assistant professor of surgery, Harvard Medical School, discusses challenges facing the development of biomarkers for patients with prostate cancer.
An important challenge facing the development of biomarkers is the potential of false positives, explains Feldman. Additionally, since there are so much data being investigated, it takes time to go through each data set, states Feldman.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on OncLive
1
Long-Term Cilta-Cel Data Show Low Rates of PFS Events in Standard-Risk R/R Myeloma
2
Nonresponse to Bridging Therapy and Peak ALC After Cilta-Cel Are Associated With Neurotoxicity, NRM in Myeloma
3
FDA Updates Axi-Cel Label to Remove Limitation of Use in R/R PCNSL
4
FDA Underscores Risks Associated With DPD Deficiency and Capecitabine/5-FU Use in Cancer Care
5




































